-
Mashup Score: 3Nivolumab-Based Therapy Drives Durable Responses in Recurrent/Metastatic Cervical Cancer - 1 year(s) ago
Nivolumab alone or in combination with ipilimumab produced encouraging responses that were maintained over time in patients with recurrent or metastatic cervical cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Nivolumab-Based Therapy Drives Durable Responses in Recurrent/Metastatic Cervical Cancer - 1 year(s) ago
Nivolumab alone or in combination with ipilimumab produced encouraging responses that were maintained over time in patients with recurrent or metastatic cervical cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nivolumab alone or in combination with ipilimumab produced encouraging responses that were maintained over time in patients with recurrent or metastatic cervical cancer. @AnaOaknin @VHIO #gyncsm #ESMO2022 https://t.co/jFjbK0OHLG
-
-
Mashup Score: 1
Dr. Hope Rugo reviews updates to data from the TROPiCS-02 trial that were recently presented at ESMO Congress 2022 and speaks to clinical implications of these data.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: @hoperugo, of @UCSFCancer, reviews updates to data from the TROPiCS-02 trial that were recently presented at #ESMO2022 and speaks to clinical implications of these data. #bcsm #oncology https://t.co/TZ9SFGNstW https://t.co/Hv7jOEA9lv
-
-
Mashup Score: 1Nivolumab-Based Therapy Drives Durable Responses in Recurrent/Metastatic Cervical Cancer - 1 year(s) ago
Nivolumab alone or in combination with ipilimumab produced encouraging responses that were maintained over time in patients with recurrent or metastatic cervical cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nivolumab-Based Therapy Drives Durable Responses in Recurrent/Metastatic Cervical Cancer @AnaOaknin @VHIO @myESMO #gyncsm #ESMO2022 https://t.co/d0EoGZX8E5
-
-
Mashup Score: 0
Mohamad Allaf, MD, discusses innovative and unique aspects of the PROSPER-RCC trial design, areas for continued analysis within the study, and the ways in which this trial will inspire and inform continued research in renal cell carcinoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
PROSPER-RCC Results May Inform Further Research on Neoadjuvant IO Approaches in RCC @allaf_mo @JohnsHopkins @myESMO #kcsm #ESMO2022 https://t.co/IhoG2x117f
-
-
Mashup Score: 0Exploring the Role of Disitamab Vedotin in the Treatment of Metastatic Urothelial Cancer - 1 year(s) ago
Disitamab vedotin is a promising antibody-drug conjugate option undergoing evaluation for patients with metastatic urothelial cancer.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Tune in to the latest episode of our Post Conference Perspectives series on #ESMO2022 as Dr Arlene Siefker-Radtke speaks on Disitamab vedotin as a promising antibody-drug conjugate option undergoing evaluation for patients with metastatic urothelial cancer https://t.co/acZSNAGWuU https://t.co/Xz0fW9rg4q
-
-
Mashup Score: 2Tumor Profiling Studies Illuminate Nuances Across Malignancies - 1 year(s) ago
Molecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods are taken up in clinical practice.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Tumor Profiling Studies Illuminate Nuances Across Malignancies @myESMO #ESMO2022 #oncology #precisionmed https://t.co/5e1NLZFiA1
-
-
Mashup Score: 1Investigators Highlight Top Advances at ESMO 2022 - 1 year(s) ago
Data presented at the ESMO Congress 2022 highlighted advances across treatment modalities, including landmark data for trials in melanoma, breast cancer, and lung cancer, as well as early data that made headlines in a subgroup of patients with colon cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Data from #ESMO2022 highlighted advances across treatment modalities, including landmark data for trials in melanoma, breast cancer, and lung cancer, as well as early data that made headlines in a subgroup of patients with CRC. @myESMO #crcsm https://t.co/vZNIY5dllm https://t.co/XOPHUJKXBd
-
-
Mashup Score: 0
Dr Domenica Lorusso reviews data updates from KEYNOTE-775 that were recently presented at the European Society for Medical Oncology (ESMO) Congress 2022.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Dr Domenica Lorusso, of @FondaPoliMi, reviews data updates from KEYNOTE-775 that were recently presented at #ESMO2022. @myESMO #oncology #MedTwitter https://t.co/AAlI9YJSxB https://t.co/YqjcA1udYR
-
-
Mashup Score: 0Investigators Highlight Top Advances at ESMO 2022 - 1 year(s) ago
Data presented at the ESMO Congress 2022 highlighted advances across treatment modalities, including landmark data for trials in melanoma, breast cancer, and lung cancer, as well as early data that made headlines in a subgroup of patients with colon cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Data from #ESMO2022 highlighted advances across treatment modalities, including landmark data for trials in melanoma, breast cancer, and lung cancer, as well as early data that made headlines in a subgroup of patients with CRC. @myESMO #crcsm https://t.co/CYLsajEryd
-
Nivolumab alone or in combination with ipilimumab produced encouraging responses that were maintained over time in patients with recurrent or metastatic cervical cancer. @AnaOaknin @VHIO #gyncsm #ESMO2022 https://t.co/Y8sk0cOD5a https://t.co/V1WHXGFWbn